Implants electrical devices that stimulate a nerve in the neck to reduce seizures and treat depression.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
Implants electrical devices that stimulate a nerve in the neck to reduce seizures and treat depression.
What this company is and how it runs — written from structure, not news.
LivaNova implants a small pulse generator in a patient's chest that sends electrical signals up a wire to an electrode wrapped around the vagus nerve in the neck, and a physician programs the device after surgery using proprietary software that records exactly how that patient's seizures or depression respond to each adjustment. Every follow-up visit adds to that record, and because the data is stored in a format tied to LivaNova's hardware, it cannot be moved to a competitor's system — so switching would mean a second surgery and starting the clinical history from scratch. Across decades of implanted patients, those accumulated records trained the stimulation algorithms that define what an effective therapy looks like, and a new entrant cannot buy or copy that dataset; they would have to run their own multi-year trials in a drug-resistant epilepsy and treatment-resistant depression population that is, by definition, small and slow to recruit. The whole system depends on insurers continuing to cover the implant procedure — if Medicare or private payers stop reimbursing the surgery, new implants stop, no new outcome data accrues, and the algorithm advantage stops compounding at precisely the moment a competitor would have the most room to catch up.
How does this company make money?
Hospitals pay for the device each time a surgeon implants one. Because the pulse generator's battery runs out after roughly 8 to 12 years, patients typically need a replacement — and the hospital buys a new device for each of those surgeries too. Clinics that manage implanted patients also purchase the dedicated programming devices needed to adjust stimulation settings at follow-up visits.
What makes this company hard to replace?
A patient who already has a device implanted would need a second surgery to remove it and replace it with a competitor's system — that is a real medical procedure with real recovery time, not a software uninstall. Neurologists and neurosurgeons who already know this system's programming protocols would have to learn an entirely different set of procedures for any competing manufacturer's device. The years of programming history and response data recorded for each patient are stored in a format tied to this company's software and cannot be transferred to an alternative platform.
What limits this company?
The patients who qualify — those who have already failed multiple medications for epilepsy or depression — form a small, hard-to-find group. Recruiting enough of them for a new study takes years, and regulators require that long-term safety and outcome data before approving any new therapeutic claim. No amount of money can make those trials go faster or replace the time it takes to train individual surgeons.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance and CE mark approval to sell neuromodulation devices in the US and Europe. It relies on biocompatible titanium and platinum materials to build the implantable components, and on lithium battery technology to power pulse generators for years inside a patient's body. Specialized neurosurgeons trained in vagus nerve electrode placement must be available to perform the surgeries. And the proprietary programming software must function correctly for physicians to adjust each device after implantation.
Who depends on this company?
Epilepsy centers at major hospitals would lose their primary implantable option for patients with drug-resistant epilepsy who have already failed multiple antiepileptic medications. Neurosurgeons in functional neurosurgery — especially those running pediatric epilepsy programs — would lose a core procedure from their practice. Neurologists treating treatment-resistant depression would lose their only FDA-approved neuromodulation device for patients who have not responded to psychotherapy or multiple rounds of medication.
How does this company scale?
Once a device design has regulatory approval, manufacturing additional pulse generators and electrodes is a straightforward production problem — more units can be built without reinventing the system. The programming software platform also extends across new devices without major added cost. What does not scale easily is training each new neurosurgeon individually and generating the multi-year patient outcome studies that regulators require before the company can make any new therapeutic claim.
What external forces can significantly affect this company?
Medicare and private insurance reimbursement decisions directly control how many implant and replacement surgeries get scheduled — a policy change cutting coverage would immediately reduce surgical volume. In Europe, the European Medical Device Regulation demands additional clinical evidence for implantable devices, adding time and cost to market access. Currency fluctuations affect manufacturing costs because the company operates facilities across multiple countries, so a shift in exchange rates can change what it costs to produce each device.
Where is this company structurally vulnerable?
If Medicare or private insurers stopped covering vagus nerve stimulation implant or replacement surgeries, hospitals would stop scheduling the procedures. No new surgeries means no new programming sessions, and no new programming sessions means the dataset stops growing. The algorithm advantage only compounds through continued implantation in a population too small to rebuild quickly — so the moment that flow of new patients stops, the lead over any competitor narrows.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph